<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11681">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954874</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2016-01595</org_study_id>
    <secondary_id>NCI-2016-01595</secondary_id>
    <secondary_id>S1418/BR006</secondary_id>
    <secondary_id>S1418</secondary_id>
    <secondary_id>S1418</secondary_id>
    <secondary_id>U10CA180888</secondary_id>
    <nct_id>NCT02954874</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer</brief_title>
  <official_title>A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With â‰¥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies how well pembrolizumab works in treating
      triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere
      with the ability of tumor cells to grow and spread.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare invasive disease-free survival (IDFS) of patients with triple-negative breast
      cancer (TNBC) who have either &gt;= 1 cm residual invasive breast cancer and/or positive lymph
      nodes (&gt; ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475
      (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire
      study population and also in the PD-L1 positive subset.

      SECONDARY OBJECTIVES:

      I. To compare the effects of MK-3475 (pembrolizumab) on overall survival (OS) and distant
      recurrence-free survival (DRFS) between the two randomized arms for the PD-L1 positive
      patients and then all patients.

      II. To assess the toxicity and tolerability of MK-3475 (pembrolizumab) in this patient
      population with or without radiation therapy.

      TERTIARY OBJECTIVES:

      I. To examine the association between biomarkers of inflammation and quality of life and
      patient reported outcomes between the two groups during and at the end of therapy.

      II. To examine the long-term and late effects of treatment on patient-reported outcomes.

      III. To collect tissue and whole blood for processing and banking in anticipation of future
      correlative studies in this patient population.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I (OBSERVATION): Patients receive no treatment but are monitored at standard clinical
      intervals during first year after randomization. Patients are examined every 12 weeks for 1
      year, and every 6 months for 4 years, then annually for 5 years.

      ARM II (PEMROLIZUMAB): Patients receive pembrolizumab intravenously (IV) over 30 minutes on
      days 1 and 22. Courses repeat every 42 days for 52 weeks in the absence of disease
      progression or unacceptable toxicity.

      All patients may undergo radiation therapy within 12 weeks of last breast cancer operation
      or after treatment.

      After completion of study treatment, patients are followed up to 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IDFS</measure>
    <time_frame>From date of randomization to date of first invasive recurrence, second invasive primary cancer (breast or not), or death due to any cause, assessed up to 10 years</time_frame>
    <description>The distributions of IDFS will be estimated using the Kaplan-Meier method, with 95% confidence intervals (CI) calculated using Greenwood's formula. Comparisons between the two treatment arms will be performed using the stratified log-rank test. The hazard ratios and 95% CIs will be based on the stratified Cox proportional hazard model with treatment as the only covariate. Secondary analyses of IDFS will be performed to describe consistency or divergence across subgroups. This will include a forest plot of treatment hazard ratios and associated 95% confidence intervals for each level of the str</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function reported by patients measured by PROMIS Global physical health scale</measure>
    <time_frame>55 weeks after randomization</time_frame>
    <description>Will be compared between the two treatment groups by means of multiple linear regression with adjustment for the corresponding baseline measurement as well as whether or not the patient received radiation therapy which is known to be associated with post-treatment fatigue. No multiple comparisons adjustment will be employed since these outcomes evaluate the toxicity of the investigational drug. The clinical meaningfulness of each comparison will be considered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of fatigue measured by Patient Reported Outcomes Measurement Information System (PROMIS) fatigue scale</measure>
    <time_frame>55 weeks after randomization</time_frame>
    <description>Will be compared between the two treatment groups by means of multiple linear regression with adjustment for the corresponding baseline measurement as well as whether or not the patient received radiation therapy which is known to be associated with post-treatment fatigue. No multiple comparisons adjustment will be employed since these outcomes evaluate the toxicity of the investigational drug. The clinical meaningfulness of each comparison will be considered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DRFS</measure>
    <time_frame>From date of randomization to date of invasive distant disease recurrence, second invasive primary cancer (breast or not) or death due to any cause, assessed up to 10 years</time_frame>
    <description>The distributions of DRFS will be estimated using the Kaplan-Meier method, with 95% CI calculated using Greenwood's formula. Comparisons between the two treatment arms will be performed using the stratified log-rank test. The hazard ratios and 95% CIs will be based on the stratified Cox proportional hazard model with treatment as the only covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional function and disease-related symptoms in patients receiving pembrolizumab assessed by PROMIS global mental health scale score</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Will be compared between the two treatment groups using a mixed model for repeated measures analysis with adjustment for the baseline score and time. Presence of treatment-by-time interaction will be investigated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment and treatment-related symptoms on physical function in patients without therapy</measure>
    <time_frame>55 weeks after randomization</time_frame>
    <description>Compared to patients receiving pembrolizumab. A multiple linear regression model will be performed with physical health scale score as an outcome and treatment and treatment related symptoms as covariates. Presence of treatment by each individual symptom item interactions will be investigated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Toxicity analysis will be conducted in all patients receiving at least one dose of MK-3475 (pembrolizumab). The incidence of adverse events will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term quality of life and symptoms between the two treatment groups</measure>
    <time_frame>Up to 60 months after randomization</time_frame>
    <description>Mixed models for repeated measures analysis will be used with adjustment for scores at 18 months to examine changes in physical and emotional domain scores, fatigue and other persistent symptoms over the course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization to date of death due to any cause, assessed up to 10 years</time_frame>
    <description>The distributions of OS will be estimated using the Kaplan-Meier method, with 95% CI calculated using Greenwood's formula. Comparisons between the two treatment arms will be performed using the stratified log-rank test. The hazard ratios and 95% CIs will be based on the stratified Cox proportional hazard model with treatment as the only covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between treatment-related symptoms and adherence to the study medication</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Will be investigated among patients randomized to pembrolizumab treatment group by means of multiple logistic regression. Patients who have been on study therapy for 70% or more of their expected time on therapy will be considered adherent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of treatment-related symptoms in patients receiving pembrolizumab</measure>
    <time_frame>18 months after randomization</time_frame>
    <description>Compared to patients without treatment. A change in severity of the particular symptom will be compared between the two treatment groups by means of multiple linear regression with adjustment for the corresponding measurement at the 55 week assessment point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of pro-inflammatory cytokines in the development of pembrolizumab associated symptoms</measure>
    <time_frame>Up to 55 weeks</time_frame>
    <description>Specifically focused on treatment-associated fatigue. This will be compared to patients in the observation group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and frequency of treatment-related symptoms (diarrhea, nausea, rash, cough, and shortness of breath, musculoskeletal pain) over time of patients receiving pembrolizumab</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Compared without treatment. The distributions of the corresponding PRO-CTCAE items will be compared between the two treatment groups using a mixed ordinal logistic regression model for repeated measures. The model will also include the corresponding baseline measurement and time. Presence of treatment-by-time interaction will be tested for each of these endpoints. Similar analyses will be performed for disease related symptoms. The descriptive and graphical methods suggested in Basch, et. al. will be used to summarize the distributions of different symptoms by treatment group over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single nucleotide polymorphisms (SNPs) in the promotor region of pro-inflammatory cytokine genes and the risk for development and severity of treatment-associated fatigue and other symptoms</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>The role of these SNPs in the persistence of long-term fatigue in all patients will also be explored using treatment assignment as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Estrogen Receptor Negative</condition>
  <condition>HER2/Neu Negative</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Progesterone Receptor Negative</condition>
  <condition>Stage 0 Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIA Breast Cancer</condition>
  <condition>Stage IIB Breast Cancer</condition>
  <condition>Stage III Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Triple-Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (observation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Courses repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (observation)</arm_group_label>
    <arm_group_label>Arm II (pembrolizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Observation</intervention_name>
    <description>Undergo standard monitoring</description>
    <arm_group_label>Arm I (observation)</arm_group_label>
    <other_name>Active Surveillance</other_name>
    <other_name>deferred therapy</other_name>
    <other_name>expectant management</other_name>
    <other_name>Observation</other_name>
    <other_name>Watchful Waiting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (observation)</arm_group_label>
    <arm_group_label>Arm II (pembrolizumab)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (observation)</arm_group_label>
    <arm_group_label>Arm II (pembrolizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Arm I (observation)</arm_group_label>
    <arm_group_label>Arm II (pembrolizumab)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>RADIATION</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEP 1 REGISTRATION

          -  Patients must have histologically confirmed estrogen receptor (ER)-, progesterone
             receptor (PR)- and HER2-negative (triple-negative, TNBC) with residual invasive
             breast cancer, as defined by the 2010 and 2013 American Society of Clinical Oncology
             (ASCO) College of American Pathologists (CAP) guidelines, after completion of
             neoadjuvant chemotherapy; residual disease must be &gt;= 1 cm in greatest dimension,
             and/or have positive lymph nodes (ypN+) observed on pathologic exam

               -  NOTE: Immunohistochemistry (IHC)-positive isolated tumor cells in the lymph node
                  (N0 [i+]) are not considered node-positive and these patients also must have &gt;=
                  1 cm residual invasive cancer in the breast in order to be eligible

          -  Patients must not have metastatic disease (i.e., must be M0)

          -  It is preferred that axillary lymph node sampling is performed after completion of
             neoadjuvant chemotherapy to allow more accurate assessment of pathologic response;
             patients must have a complete axillary lymph node dissection after neoadjuvant
             chemotherapy in the following situations (exceptions will be granted for patients
             participating in the Alliance A11202 trial):

               -  Patients had documented pathologic involvement of the axillary nodes (fine
                  needle aspiration [FNA] or core biopsy) before neoadjuvant chemotherapy and had
                  sentinel node biopsy after neoadjuvant chemotherapy with positive sentinel
                  node(s)

               -  Patient had documented pathologic involvement of the axillary nodes (FNA or core
                  biopsy) before neoadjuvant chemotherapy and had only 1 sentinel lymph node
                  removed after neoadjuvant chemotherapy

                    -  NOTE: Patients who undergo sentinel node biopsy before starting neoadjuvant
                       treatment and do not undergo post neoadjuvant assessment of the axillary
                       nodes or who have negative axillary nodes on post neoadjuvant assessment
                       must have &gt;= 1 cm residual invasive cancer in the breast after completion
                       of neoadjuvant chemotherapy

          -  Patients must have a minimum of five, available unstained slides from the residual
             (post-neoadjuvant) invasive tumor in primary site or lymph node to be submitted
             within 7 days after registration to determine PD-L1 expression; the tumor tissue must
             be adequate for PD-L1 testing, which typically requires a minimum of 100 cancer cells
             per slide

          -  Patients must be offered the opportunity to participate in specimen banking

          -  Patients must have had neoadjuvant chemotherapy followed by surgery; the recommended
             neoadjuvant treatment should include 16-24 weeks of a third generation chemotherapy
             regimen as recommended by National Comprehensive Cancer Network (NCCN) guidelines for
             triple negative breast cancer (examples include dose dense adriamycin-cytoxan [AC]
             followed by dose-dense paclitaxel; weekly paclitaxel x 12 followed or preceded by
             cyclophosphamide-adriamycin-fluorouracil [FAC], fluorouracil-epirubicin-cytoxan
             [FEC], AC or dose dense AC; docetaxel either followed or preceded by FEC/FAC or AC;
             carboplatin-containing neoadjuvant chemotherapy is also allowed); patients who cannot
             complete all planned treatment cycles for any reason are considered high risk and
             therefore are eligible for the study if they have residual disease; patients must
             have resolution of adverse event(s) of the most recent prior chemotherapy to grade 1
             or less, except alopecia and =&lt; grade 2 neuropathy which are allowed

          -  Patients may receive post-operative (adjuvant) chemotherapy for up to 24 weeks of
             duration (e.g. 8 cycles of capecitabine as in the CREATE-X trial) after completion of
             surgery at the discretion of the treating physician; patients must have resolution of
             adverse event(s) of the most recent prior chemotherapy to grade 1 or less, except
             alopecia and =&lt; grade 2 neuropathy which are allowed; adjuvant chemotherapy, if
             administered, must have been completed within 35 days prior to screening registration
             and must be given prior to radiation

          -  Patients must have completed their final breast surgery (rendering them free from
             disease) with clear resection margins for invasive cancer and ductal carcinoma in
             situ (DCIS) within 90 days prior to screening registration for patients not receiving
             post-operative (adjuvant) chemotherapy, or within 210 days prior to screening
             registration for patients who have completed post-operative (adjuvant) chemotherapy;
             positive margins are allowed only if the surgical team of the patient deems further
             resection impossible

          -  Patients for whom radiation therapy (RT) to the affected breast or chest wall and
             regional nodal areas is clinically indicated as per NCCN treatment guidelines, should
             receive RT after randomization when possible, concomitant with MK-3475
             (pembrolizumab) if randomized to the experimental arm; however, RT administered prior
             to registration is also allowed; patients must specify at the time of screening
             registration whether or not they will receive RT and the extent of intended RT

          -  Patients must not have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4
             or similar drugs; patients must not be planning to receive any of the prohibited
             therapies during the screening or treatment phases of the study

          -  Patients must not be planning to receive concomitantly other biologic therapy,
             hormonal therapy, other chemotherapy, surgery or other anti-cancer therapy except
             radiation therapy while receiving treatment on this protocol

          -  Patients must have Zubrod performance status =&lt; 2

          -  Patients must not have a history of (non-infectious) pneumonitis that required
             steroids or evidence of active pneumonitis

          -  Patients must not have an active infection requiring systemic therapy

          -  Patients must not have active autoimmune disease that has required systemic treatment
             in past 2 years (i.e., with use of disease modifying agents, corticosteroids or
             immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or
             physiologic corticosteroid replacement therapy for adrenal or pituitary
             insufficiency, etc.) is not considered a form of systemic treatment

          -  Patients must not have received live vaccines within 30 days prior to registration;
             examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin
             (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are
             generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed

          -  Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus
             (HCV) infection prior to registration; patients who have completed curative therapy
             for HCV are eligible; patients with known human immunodeficiency virus (HIV)
             infection are eligible if they meet each of the following 3 criteria:

               -  CD4 counts &gt;= 350 mm^3

               -  Serum HIV viral load of &lt; 25,000 IU/ml and

               -  Treated on a stable antiretroviral regimen

          -  No other prior invasive malignancy is allowed except for the following: adequately
             treated basal (or squamous cell) skin cancer, in situ breast or cervical cancer;
             stage I or II invasive cancer treated with a curative intent without evidence of
             disease recurrence for at least five years

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent for this protocol in accordance with institutional
             and federal guidelines

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system

          -  STEP 2 REGISTRATION

          -  Patients must not be registered to step 2 until receiving confirmation from the
             Southwest Oncology Group (SWOG) Statistical Center that the patient's tissue specimen
             was adequate for PD-L1 testing; patients must be registered within 7 days of
             receiving the e-mail notification confirming submission was evaluable for PD-L1
             status

          -  A serum thyroid-stimulating hormone (TSH) must be obtained within 28 days prior to
             step 2 registration to obtain a baseline value

          -  Absolute neutrophil count (ANC) &gt;= 1,500 microliter (mcL)

          -  Platelets &gt;= 100,000/mcL

          -  Hemoglobin &gt;= 9 g/dL

          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (IULN) (except Gilbert's
             syndrome, who must have a total bilirubin &lt; 3.0 mg/dL)

          -  Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 2.5
             x IULN

          -  Alkaline phosphatase =&lt; 2.5 x IULN

          -  Serum creatinine =&lt; IULN OR measured or calculated creatinine clearance &gt;= 60 mL/min

          -  Women of childbearing potential must have a negative urine or serum pregnancy test
             within 28 day prior to registration; women/men of reproductive potential must have
             agreed to use an effective contraceptive method for the course of the study through
             120 days after the last dose of study medication; should a woman become pregnant or
             suspect she is pregnant while she or her partner is participating in this study, she
             should inform her treating physician immediately; a woman is considered to be of
             &quot;reproductive potential&quot; if she has had menses at any time in the preceding 12
             consecutive months; in addition to routine contraceptive methods, &quot;effective
             contraception&quot; also includes heterosexual celibacy and surgery intended to prevent
             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
             bilateral oophorectomy, bilateral tubal ligation, or vasectomy; however, if at any
             point a previously celibate patient chooses to become heterosexually active during
             the time period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures; patients must not be pregnant or
             nursing due to unknown teratogenic side effects

          -  Site must verify that there is no known change in the step 1 eligibility since
             initial registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lajos Pusztai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairbanks Memorial Hospital</name>
      <address>
        <city>Fairbanks</city>
        <state>Alaska</state>
        <zip>99701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Keech</last_name>
      <phone>253-403-2394</phone>
    </contact>
    <investigator>
      <last_name>John A. Keech</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group-Rogers</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph T. Beck</last_name>
      <phone>800-381-6939</phone>
    </contact>
    <investigator>
      <last_name>Joseph T. Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Auburn Faith Hospital</name>
      <address>
        <city>Auburn</city>
        <state>California</state>
        <zip>95602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIS Cancer Center at San Joaquin Community Hospital</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen K. Chew</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Helen K. Chew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center-Herrick Campus</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mills - Peninsula Hospitals</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne E. Mortimer</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Joanne E. Mortimer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fremont - Rideout Cancer Center</name>
      <address>
        <city>Marysville</city>
        <state>California</state>
        <zip>95901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen K. Chew</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Helen K. Chew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation-Camino Division</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Research Consortium</name>
      <address>
        <city>Novato</city>
        <state>California</state>
        <zip>94945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaitali S. Nangia</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Chaitali S. Nangia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation Health Care</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Roseville Medical Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen K. Chew</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Helen K. Chew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center-Pacific Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation-Santa Cruz</name>
      <address>
        <city>Santa Cruz</city>
        <state>California</state>
        <zip>95065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation-Sunnyvale</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gene Upshaw Memorial Tahoe Forest Cancer Center</name>
      <address>
        <city>Truckee</city>
        <state>California</state>
        <zip>96161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen K. Chew</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Helen K. Chew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Solano Medical Center/Cancer Center</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penrose-Saint Francis Healthcare</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony D. Elias</last_name>
      <phone>720-848-0650</phone>
    </contact>
    <investigator>
      <last_name>Anthony D. Elias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danijela Jelovac</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Danijela Jelovac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regan D. Rostorfer</last_name>
      <phone>321-841-7246</phone>
      <email>CancerClinicalTrials@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Regan D. Rostorfer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lewis Cancer and Research Pavilion at Saint Joseph's/Candler</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard A. Zaren</last_name>
      <phone>912-819-5704</phone>
    </contact>
    <investigator>
      <last_name>Howard A. Zaren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Georgia Medical Center/Pearlman Cancer Center</name>
      <address>
        <city>Valdosta</city>
        <state>Georgia</state>
        <zip>31602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel N. Ofori</last_name>
      <phone>229-259-4628</phone>
      <email>maryann.heddon@sgmc.org</email>
    </contact>
    <investigator>
      <last_name>Samuel N. Ofori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Bloomington</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Canton</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Carthage</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centralia Oncology Clinic</name>
      <address>
        <city>Centralia</city>
        <state>Illinois</state>
        <zip>62801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of Decatur</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crossroads Cancer Center</name>
      <address>
        <city>Effingham</city>
        <state>Illinois</state>
        <zip>62401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Eureka</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Galesburg</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Kewanee Clinic</name>
      <address>
        <city>Kewanee</city>
        <state>Illinois</state>
        <zip>61443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Macomb</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Ottawa Clinic</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Pekin</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peru</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Princeton</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SwedishAmerican Regional Cancer Center/ACT</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harvey E. Einhorn</last_name>
      <phone>779-696-9400</phone>
      <email>cancercare@swedishamerican.org</email>
    </contact>
    <investigator>
      <last_name>Harvey E. Einhorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Illinois-Swansea</name>
      <address>
        <city>Swansea</city>
        <state>Illinois</state>
        <zip>62226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Greeley Medical Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-William R Bliss Cancer Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Boone</name>
      <address>
        <city>Boone</city>
        <state>Iowa</state>
        <zip>50036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-West Des Moines</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center-West Lakes</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greater Regional Medical Center</name>
      <address>
        <city>Creston</city>
        <state>Iowa</state>
        <zip>50801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Medical Center - East Campus</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Kovach</last_name>
      <phone>800-446-6088</phone>
      <email>werners@genesishealth.com</email>
    </contact>
    <investigator>
      <last_name>George Kovach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Behrens</last_name>
      <phone>515-282-2921</phone>
    </contact>
    <investigator>
      <last_name>Robert J. Behrens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Behrens</last_name>
      <phone>515-282-2921</phone>
    </contact>
    <investigator>
      <last_name>Robert J. Behrens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Laurel</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center - Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Trinity Cancer Center</name>
      <address>
        <city>Fort Dodge</city>
        <state>Iowa</state>
        <zip>50501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Jefferson</name>
      <address>
        <city>Jefferson</city>
        <state>Iowa</state>
        <zip>50129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Marshalltown</name>
      <address>
        <city>Marshalltown</city>
        <state>Iowa</state>
        <zip>50158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center-West Lakes</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Wichita Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaker R. Dakhil</last_name>
      <phone>316-268-5374</phone>
    </contact>
    <investigator>
      <last_name>Shaker R. Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital East</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>800-998-2119</phone>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LSU Health Baton Rouge-North Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Hanson</last_name>
      <phone>225-215-1353</phone>
      <email>clinicalresearch@marybird.com</email>
    </contact>
    <investigator>
      <last_name>David S. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Hematology Oncology Associates LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Hanson</last_name>
      <phone>225-215-1353</phone>
      <email>clinicalresearch@marybird.com</email>
    </contact>
    <investigator>
      <last_name>David S. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Bird Perkins Cancer Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Hanson</last_name>
      <phone>225-215-1353</phone>
      <email>clinicalresearch@marybird.com</email>
    </contact>
    <investigator>
      <last_name>David S. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Hanson</last_name>
      <phone>225-215-1353</phone>
      <email>clinicalresearch@marybird.com</email>
    </contact>
    <investigator>
      <last_name>David S. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Health Center-Summa</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John T. Cole</last_name>
      <phone>888-562-4763</phone>
    </contact>
    <investigator>
      <last_name>John T. Cole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates Inc</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Hanson</last_name>
      <phone>225-215-1353</phone>
      <email>clinicalresearch@marybird.com</email>
    </contact>
    <investigator>
      <last_name>David S. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Center of The South Incorporated</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Hanson</last_name>
      <phone>225-215-1353</phone>
      <email>clinicalresearch@marybird.com</email>
    </contact>
    <investigator>
      <last_name>David S. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John T. Cole</last_name>
      <phone>888-562-4763</phone>
    </contact>
    <investigator>
      <last_name>John T. Cole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Maine</state>
        <zip>03909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn A. McLaughlin</last_name>
      <phone>207-351-3777</phone>
    </contact>
    <investigator>
      <last_name>Marilyn A. McLaughlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A. Riseberg</last_name>
      <phone>410-951-7950</phone>
      <email>prc@mdmercy.com</email>
    </contact>
    <investigator>
      <last_name>David A. Riseberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana H. Griffiths</last_name>
      <phone>410-368-2910</phone>
    </contact>
    <investigator>
      <last_name>Diana H. Griffiths</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danijela Jelovac</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Danijela Jelovac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frederick Memorial Hospital</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian M. O'Connor</last_name>
      <phone>240-566-3584</phone>
      <email>clinicaltrials@fmh.org</email>
    </contact>
    <investigator>
      <last_name>Brian M. O'Connor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrine L. Zarwan</last_name>
      <phone>781-744-8027</phone>
    </contact>
    <investigator>
      <last_name>Corrine L. Zarwan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard M. Zuniga</last_name>
      <phone>978-788-7084</phone>
      <email>ghincks@lowellgeneral.org</email>
    </contact>
    <investigator>
      <last_name>Richard M. Zuniga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne F. Schott</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Anne F. Schott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caro Cancer Center</name>
      <address>
        <city>Caro</city>
        <state>Michigan</state>
        <zip>48723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Chelsea</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants-Clarkston</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newland Medical Associates-Clarkston</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University Clinical Center</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824-7016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deimante M. Tamkus</last_name>
      <phone>517-975-9547</phone>
    </contact>
    <investigator>
      <last_name>Deimante M. Tamkus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Cancer Management Specialists-Van Elslander Cancer Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Hospital</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates East PC</name>
      <address>
        <city>Macomb Township</city>
        <state>Michigan</state>
        <zip>48044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monroe Cancer Center</name>
      <address>
        <city>Monroe</city>
        <state>Michigan</state>
        <zip>48162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey H. Muler</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey H. Muler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology-Pontiac</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hope Cancer Center</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newland Medical Associates-Pontiac</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Reed City Hospital</name>
      <address>
        <city>Reed City</city>
        <state>Michigan</state>
        <zip>49677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's of Michigan</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Saginaw Valley PC</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Munson Medical Center</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Cancer Management Specialists-Macomb Professional Building</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Macomb-Oakland Hospital</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Oncology/Hematology Associates of West Branch</name>
      <address>
        <city>West Branch</city>
        <state>Michigan</state>
        <zip>48661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Ann Arbor</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M. Reynolds</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic North-Bemidgi</name>
      <address>
        <city>Bemidji</city>
        <state>Minnesota</state>
        <zip>56601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6161</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Cancer Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Saint Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miller-Dwan Hospital</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview-Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview Maple Grove Medical Center</name>
      <address>
        <city>Maple Grove</city>
        <state>Minnesota</state>
        <zip>55369</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital - Healtheast</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Partners Inc</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Ulm Medical Center</name>
      <address>
        <city>New Ulm</city>
        <state>Minnesota</state>
        <zip>56073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Health Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic - Saint Louis Park</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Regional Medical Center</name>
      <address>
        <city>Shakopee</city>
        <state>Minnesota</state>
        <zip>55379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeview Hospital</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rice Memorial Hospital</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview Lakes Medical Center</name>
      <address>
        <city>Wyoming</city>
        <state>Minnesota</state>
        <zip>55092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth D. Cohen</last_name>
      <phone>732-923-7689</phone>
    </contact>
    <investigator>
      <last_name>Seth D. Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Memorial</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James W. Lee</last_name>
      <phone>609-914-6762</phone>
    </contact>
    <investigator>
      <last_name>James W. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James W. Lee</last_name>
      <phone>609-914-6762</phone>
    </contact>
    <investigator>
      <last_name>James W. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lovelace Medical Center-Saint Joseph Square</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presbyterian Kaseman Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center - Las Cruces</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Saint Vincent Regional Cancer Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Ursa A. Brown-Glaberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnot Ogden Medical Center/Falck Cancer Center</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William T. Muuse</last_name>
      <phone>607-271-7000</phone>
    </contact>
    <investigator>
      <last_name>William T. Muuse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orange Regional Medical Center</name>
      <address>
        <city>Middletown</city>
        <state>New York</state>
        <zip>10940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey M. Stewart</last_name>
      <phone>845-342-7609</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey M. Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Adams</last_name>
      <phone>212-263-4434</phone>
      <email>prmc.coordinator@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sylvia Adams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dickstein Cancer Treatment Center</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Costin</last_name>
      <phone>914-849-7582</phone>
      <email>mcortese@wphospital.org</email>
    </contact>
    <investigator>
      <last_name>Dan Costin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Randolph Hospital</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinay K. Gudena</last_name>
      <phone>336-832-0821</phone>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center at Alamance Regional</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinay K. Gudena</last_name>
      <phone>336-832-0821</phone>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinay K. Gudena</last_name>
      <phone>336-832-0821</phone>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Heath Cancer Center at Mebane</name>
      <address>
        <city>Mebane</city>
        <state>North Carolina</state>
        <zip>27302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinay K. Gudena</last_name>
      <phone>336-832-0821</phone>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Annie Penn Memorial Hospital</name>
      <address>
        <city>Reidsville</city>
        <state>North Carolina</state>
        <zip>27320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinay K. Gudena</last_name>
      <phone>336-832-0821</phone>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strecker Cancer Center-Belpre</name>
      <address>
        <city>Belpre</city>
        <state>Ohio</state>
        <zip>45714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adena Regional Medical Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Carmel East Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Oncology and Hematology Associates Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mark H Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health Center West</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Health Center-Grady Cancer Center</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth Mansfield Hospital</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marietta Memorial Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Ohio</state>
        <zip>45750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OneHealth Marion General Hospital</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Knox Community Hospital</name>
      <address>
        <city>Mount Vernon</city>
        <state>Ohio</state>
        <zip>43050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Licking Memorial Hospital</name>
      <address>
        <city>Newark</city>
        <state>Ohio</state>
        <zip>43055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Ohio Medical Center</name>
      <address>
        <city>Portsmouth</city>
        <state>Ohio</state>
        <zip>45662</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flower Hospital</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey H. Muler</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey H. Muler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital/Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey H. Muler</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey H. Muler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Ann's Hospital</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Healthcare System Cancer Care Center</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Oncology and Hematology Care Southeast</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary E. Goodman</last_name>
      <phone>206-215-3086</phone>
      <email>PCRC-NCORP@Swedish.org</email>
    </contact>
    <investigator>
      <last_name>Gary E. Goodman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Newberg Medical Center</name>
      <address>
        <city>Newberg</city>
        <state>Oregon</state>
        <zip>97132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary E. Goodman</last_name>
      <phone>206-215-3086</phone>
      <email>PCRC-NCORP@Swedish.org</email>
    </contact>
    <investigator>
      <last_name>Gary E. Goodman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary E. Goodman</last_name>
      <phone>206-215-3086</phone>
      <email>PCRC-NCORP@Swedish.org</email>
    </contact>
    <investigator>
      <last_name>Gary E. Goodman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Saint Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary E. Goodman</last_name>
      <phone>206-215-3086</phone>
      <email>PCRC-NCORP@Swedish.org</email>
    </contact>
    <investigator>
      <last_name>Gary E. Goodman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep H. Mashru</last_name>
      <phone>503-335-2400</phone>
    </contact>
    <investigator>
      <last_name>Sandeep H. Mashru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SWOG</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lajos Pusztai</last_name>
      <phone>203-785-5702</phone>
    </contact>
    <investigator>
      <last_name>Lajos Pusztai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence P. Cescon</last_name>
      <phone>610-988-9323</phone>
    </contact>
    <investigator>
      <last_name>Terrence P. Cescon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Laurens</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Easley</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert D. Siegel</last_name>
      <phone>864-255-1713</phone>
    </contact>
    <investigator>
      <last_name>Robert D. Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Butternut</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert D. Siegel</last_name>
      <phone>864-255-1713</phone>
    </contact>
    <investigator>
      <last_name>Robert D. Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center-Oncology Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6161</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6161</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center Cool Springs</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent N. Rexer</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Brent N. Rexer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent N. Rexer</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Brent N. Rexer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent N. Rexer</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Brent N. Rexer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Don and Sybil Harrington Cancer Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian T. Pruitt</last_name>
      <phone>806-212-1985</phone>
      <email>gcravey@harringtoncc.org</email>
    </contact>
    <investigator>
      <last_name>Brian T. Pruitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Memorial Regional Medical Center</name>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William J. Irvin</last_name>
      <phone>804-594-4900</phone>
    </contact>
    <investigator>
      <last_name>William J. Irvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Saint Francis Medical Center</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William J. Irvin</last_name>
      <phone>804-594-4900</phone>
    </contact>
    <investigator>
      <last_name>William J. Irvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Saint Mary's Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William J. Irvin</last_name>
      <phone>804-594-4900</phone>
    </contact>
    <investigator>
      <last_name>William J. Irvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Gralow</last_name>
      <phone>800-804-8824</phone>
    </contact>
    <investigator>
      <last_name>Julie R. Gralow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance at EvergreenHealth</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Gralow</last_name>
      <phone>800-804-8824</phone>
    </contact>
    <investigator>
      <last_name>Julie R. Gralow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Gralow</last_name>
      <phone>800-804-8824</phone>
    </contact>
    <investigator>
      <last_name>Julie R. Gralow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Gralow</last_name>
      <phone>800-804-8824</phone>
    </contact>
    <investigator>
      <last_name>Julie R. Gralow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center-First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary E. Goodman</last_name>
      <phone>206-215-3086</phone>
      <email>PCRC-NCORP@Swedish.org</email>
    </contact>
    <investigator>
      <last_name>Gary E. Goodman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance at Northwest Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Gralow</last_name>
      <phone>800-804-8824</phone>
    </contact>
    <investigator>
      <last_name>Julie R. Gralow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Gralow</last_name>
      <phone>800-804-8824</phone>
    </contact>
    <investigator>
      <last_name>Julie R. Gralow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spokane Valley Cancer Center-Mayfair</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Gralow</last_name>
      <phone>800-804-8824</phone>
    </contact>
    <investigator>
      <last_name>Julie R. Gralow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProHealth D N Greenwald Center</name>
      <address>
        <city>Mukwonago</city>
        <state>Wisconsin</state>
        <zip>53149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy R. Wassenaar</last_name>
      <phone>262-928-5539</phone>
      <email>Chanda.miller@phci.org</email>
    </contact>
    <investigator>
      <last_name>Timothy R. Wassenaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Western Wisconsin</name>
      <address>
        <city>New Richmond</city>
        <state>Wisconsin</state>
        <zip>54017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProHealth Oconomowoc Memorial Hospital</name>
      <address>
        <city>Oconomowoc</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy R. Wassenaar</last_name>
      <phone>262-928-5539</phone>
      <email>Chanda.miller@phci.org</email>
    </contact>
    <investigator>
      <last_name>Timothy R. Wassenaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProHealth Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy R. Wassenaar</last_name>
      <phone>262-928-5539</phone>
      <email>Chanda.miller@phci.org</email>
    </contact>
    <investigator>
      <last_name>Timothy R. Wassenaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Cancer Center at ProHealth Care</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy R. Wassenaar</last_name>
      <phone>262-928-5539</phone>
      <email>Chanda.miller@phci.org</email>
    </contact>
    <investigator>
      <last_name>Timothy R. Wassenaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>November 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
